上海君赛生物股份有限公司

本网站使用cookie。继续浏览本网站，即表示您同意我们使用cookies。有关cookies的更多细节以及如何管理它们，请参阅我们的《隐私条款》。

中

En

关于君赛

公司简介

创始人

硬件设施

发展历程

企业文化

企业荣誉

核心技术

技术平台

产品管线

学术成果

临床试验

新闻动态

公司新闻

媒体报道

人才招聘

社会招聘

校园招聘

联系我们

2026 ASGCT 3101：Stable and efficient gene modification of tumor-infiltrating lymphocytes across multiple cancer types using non-viral electroporation-based NovaGMP platform

点击下载
2026 AACR 3699: The "Preservation & Expansion" Process: A Key Milestone for Enhancing Accessibility of Autologous Tumor-Infiltrating Lymphocyte Therapy by Enabling Long-Term Cryopreservation of Seed Cells

点击下载
2026 ELCC 219eTiP: Trial in Progress：A Phase Ib, Open-label, Single-arm Trial of Autologous Natural Tumor-Infiltrating Lymphocyte Injection (GC101) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (MIZAR-005)

点击下载
2025 ESMO-IO 80P: A Phase I Trial of Optimized Autologous Tumor-Infiltrating Lymphocyte Therapy Without Exogenous IL-2 in Patients with Advanced Non-Small Cell Lung Cancer

点击下载
2025 ESMO Asia 818TiP：Trial in progress: A Pivotal Phase 2, Randomized, Controlled, Open-Label, Trial (MIZAR-003) to Assess the Efficacy and Safety of GC101 TIL, an Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy, for Patients with Advanced Anti-PD-1 Refractory Melanoma in Later-Line Therapy

点击下载

1